Nanotechnology Tools for Infection Control
Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance
- 1st Edition - August 26, 2024
- Imprint: Elsevier
- Editors: Alessandro Poma, Loris Rizzello
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 9 9 4 - 0
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 9 9 5 - 7
Nanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance provides an overview of recent st… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteNanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance provides an overview of recent strategies to build nanotechnology platforms, with a specific focus on biocompatible and biodegradable nanosystems. Particular attention is given to responsive nanoparticles, which are able to sense and respond to specific external stimuli (e.g., temperature, pH). The book includes details of the rationale behind the design of the raw materials, synthetic procedures and characterization techniques. It also introduces a new generation of nanomaterials, commonly named as ‘nanobots’, which are able to self-propel in response to external stimuli.
Subsequent sections of the book focus on the applications of nanosystems as an alternative approach to standard antibiotics. The chapters describe their pharmokinetic and dynamics within the body, their ability to cross biological barriers and how they distribute within different body compartments. In this respect, a dedicated section highlights the crucial role of the immune system, as well as of protein corona, in changing the nanoparticles retention within the body. Coverage is also given to describe how nanosystems access different cells and their intracellular trafficking.
- Provides an overview of the current challenges in infection and immunity, showing how nanosystems can be used to meet them
- Focuses on the translational potential of nanotechnology for both clinical and commercial applications
- Assesses the major challenges of effectively using nanotechnology in immunology
Materials Scientists and Engineers / Micro- and Nanotechnologies, Fundamental Life Sciences / Immunology
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- 1. Introduction
- 2. The significant drain in antimicrobial discovery by pharma companies
- 1. Introduction and historical background
- 2. Challenges and role of drugmakers
- 3. Quest for antimicrobial drug design
- 4. Pharmaceutical development in a ‘green way’
- 5. New technologies, devices for diagnostics and toxicology
- 6. Active public and private initiatives against AMR
- 7. Final remarks and perspectives
- 3. Design and production of nanoparticles
- 1. Choice of material
- 2. Nanoparticles
- 3. Production of nanoparticles
- 4. Examples of commercialised applications
- 4. Nanoparticle characterisation and standardisation
- 1. Introduction
- 2. Sample preparation
- 3. Measurements of nanoparticle properties
- 4. Considerations when selecting a technique
- 5. Standardisation
- 6. Conclusion and perspectives
- 5. Navigating the nanoscale: Principles of body navigation
- 1. Introduction
- 2. Modulating nanoparticle pharmacodynamics: Avoiding liver and RES clearance
- 3. Brain targeting: Crossing the blood–brain barrier
- 4. Brain targeting: Delivery, targeting and efflux within the brain parenchyma
- 5. Tumour targeting: Peripheral cancers
- 6. Immune system targeting
- 6. Intracellular fate of nanosystems, their degradation and body accumulation
- 1. Introduction
- 2. The fate of nanoparticles
- 3. Concluding remarks
- 7. Molecular targets and pharmacodynamics for bactericidal and bacteriostatic activity
- 1. Antimicrobial agents, mechanisms and modes of delivery
- 2. Applications of antimicrobial nanoparticles, pharmacodynamics and safety
- 3. Material antimicrobial testing
- 4. Conclusions
- 8. How to fight bacteria without inducing drug resistance?
- 1. Introduction
- 2. The antimicrobial resistance crisis: Why are we there?
- 3. How to develop antibiotic therapies with low selective pressure
- 4. Conclusions
- 9. Pre-clinical characterisation: Which animal model is best for infection?
- 1. Zebrafish, a tiny vertebrate star
- 2. Why studying NPs in the zebrafish
- 3. Zebrafish, nanoparticles and intracellular infections
- 4. Conventional models
- 10. Clinical translation and envisioned impact of nanotech for infection control: Economy, government policy and public awareness
- 1. Introduction: Why nanotechnology against infections?
- 2. The background of the resistance problem and perception of nanotech
- 3. Nanotoxicology, environmental risks and regulatory policy
- 4. Economical perspective towards clinical translation
- 5. Conclusions
- Index
- Edition: 1
- Published: August 26, 2024
- Imprint: Elsevier
- No. of pages: 412
- Language: English
- Paperback ISBN: 9780128239940
- eBook ISBN: 9780128239957
AP
Alessandro Poma
Alessandro Poma received his MSc in Pharmaceutical Technology and Chemistry from the University of Palermo (Italy) in 2009. He then joined the Cranfield Biotechnology Group led by Prof. Sergey Piletsky to undertake a PhD in Biosensors and Nanomaterials (Cranfield University, 2013). He moved to UCL in 2014, first as an NC3Rs David Sainsbury Fellow and subsequently in other roles, and he has been appointed Lecturer in Biomaterials and Allied Subjects in the Division of Biomaterials and Tissue Engineering in 2019. His key research area is the development of molecularly imprinted nanomaterials as synthetic antibodies, and their polymeric biodegradable composites for diagnostic, therapeutic and tissue engineering applications
Affiliations and expertise
Division of Biomaterials and Tissue Engineering, Eastman Dental Institute, University College London, UKLR
Loris Rizzello
Loris Rizzello received his MSc (Magna cum Laude) in Biotechnology at the University of Salento (Italy) in 2008, and the PhD in nanoscience at the Italian institute of Technology (IIT) in 2012. He then joined the University College London (UCL), Department of Chemistry, as International Newton Postdoctoral Fellow (by The Royal Society) under the supervision of Prof. Giuseppe Battaglia. He moved to the Institute for Bioengineering of Catalonia (IBEC) of Barcelona as a Marie Curie Fellow in 2018.
He has been appointed as Associate Professor of Protein Engineering and ERC-StG grantee at the University of Milan, Department of Pharmaceutical Science, since October 2020. From March 2021, he is also Junior Group Leader at National Institute of Molecular Genetics of Milan (INGM), where he leads the Infection Dynamics Laboratory. His key research area is the use of cell-derived biomimetic nanoparticles for the treatment of intracellular pathogens infections, with a focus on the eradication of human tuberculosis. He also investigates the innate and adaptive immune response to Mycobacteria infections.
Affiliations and expertise
University of Milan, Department of Pharmaceutical Science (DISFARM), Italy.Read Nanotechnology Tools for Infection Control on ScienceDirect